Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Benfotiamine is a synthetic fat-soluble derivative of thiamine (vitamin B1), specifically an S-acyl derivative known as S-benzoylthiamine O-monophosphate. It is more bioavailable than standard thiamine salts and is primarily used to increase thiamine levels in the body. After oral administration and dephosphorylation in the intestine and liver, it is converted to active thiamine. Its main mechanism involves increasing transketolase activity in peripheral tissues via the pentose phosphate pathway. This action helps reduce hyperglycemic damage by blocking pathways such as hexosamine formation, advanced glycation end product (AGE) formation, and diacylglycerol-protein kinase C activation. Clinically, benfotiamine has been investigated for diabetic neuropathy and other diabetes-related complications; it may improve symptoms of diabetic polyneuropathy but evidence for other indications remains limited[1][3][5][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on benfotiamine.